AI Analysis
AI-generated analysis. Always verify with the original filing.
Evogene Ltd. received a Nasdaq non-compliance notice for its ordinary shares trading below $1.00 per share for 30 consecutive business days, triggering a 180-day cure period ending September 28, 2026, during which it must achieve a $1.00+ closing bid price for ten consecutive business days to avoid delisting.
Key Takeaways
1Nasdaq notified Evogene of non-compliance with Rule 5550(a)(2) due to a sustained sub-$1.00 closing bid price — a formal listing deficiency requiring remediation.
2The Company has until September 28, 2026 (180 calendar days from April 2, 2026) to regain compliance; failure may lead to delisting unless eligible for a second compliance period.
3Compliance can be achieved solely by maintaining a $1.00+ closing bid price for ten consecutive business days — no other metrics or filings are required for initial cure.
4Evogene stated it may consider a reverse stock split among other alternatives, but no board action or shareholder approval has been announced or taken.